Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Small Cell Lung Cancer.

Trial Profile

Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Bortezomib (Primary) ; Carboplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Nov 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Planned end date changed from 1 Jul 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top